Digene's Hybrid Capture® 2 CT and GC DNA Tests:
The Next Generation in Screening for Chlamydia and Gonorrhea
 Using a single specimen, Digene's Hybrid Capture® (hc) 2 CT and GC DNA Tests identifies the two most common bacterial infections of the lower genital tract, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Although many women with CT or GC are asymptomatic, these infections may cause upper genital tract complications including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.
Recent studies show that screening asymptomatic, adolescent women reduces upper genital tract complications by 60%. Digene's Hybrid Capture® 2 CT and GC tests use one sample to screen for the DNA of both bacteria, either combined or individually. The hc2 system also offers testing for HPV (human papillomavirus) from the same specimen, providing the capability of comprehensive CT, GC and HPV screening in a single office visit.
CT Sensitivity and Specificity
| Chlamydia
trachomatis (CT) |
|
Hc2 CT-ID DNA
Test |
| Sensitivity |
|
| - Brush |
92.3% |
| - Swab |
97.7% |
| Specificity |
|
| - Brush |
98.2% |
| - Swab |
98.6% |
GC Sensitivity and Specificity
| Neisseria
gonorrhea (GC) |
|
Hc2 GC-ID DNA
Test |
| Sensitivity |
|
| - Brush |
92.6% |
| - Swab |
95.2% |
| Specificity |
|
| - Brush |
98.5% |
| - Swab |
98.9% |
Test performance (female endocervical specimens–symptomatic and asymptomatic)
| Digene's Hybrid Capture® 2 CT/GC DNA Test uses the only FDA–cleared technology that can identify HPV, CT and GC DNA from a single patient specimen.* |
Collection options:
When screening women for CT and GC, use Digene's DNA Collection Device. This single–specimen collection device can be used to obtain CT, GC and HPV patient results.*
Reimbursement:
Digene's hc2 CT and GC tests are recognized by the American Medical Association (AMA) and are reimbursed using "Amplified Probe Technique" CPT codes (when appropriate).
back to top
|